ArticleAlzheimer's research & therapy2011

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.

François Piette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.